HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Medicis Pharmaceutical's Triaz

This article was originally published in The Rose Sheet

Executive Summary

Medicis Pharmaceutical's Triaz: Phoenix, AZ-based dermatology and skin care Rx and OTC company announces availability of prescription Triaz for treatment of acne. Triaz gel contains 6% or 10% benzoyl peroxide, 5% glycolic acid and 2% zinc acetate. Triaz cleanser contains 10% benzoyl peroxide. The average wholesale price for the 6% gel and 10% gel is $18.60 and $19.20, respectively, and AWP for the cleanser is $9.60. Medicis' 26-person sales force details exclusively to dermatologists. The company says its dedicated sales force is the fifth largest in dermatology. Medicis' other products include Esoterica medicated skin fade cream. Consolidated sales for the three months were up 24% to $4.6 mil., while net income rose to $645,979 from $25,501 a year ago, Medicis reported Oct. 31...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel